interleukin 1beta (193-195) has been researched along with interleukin-8 in 1 studies
| Studies (interleukin 1beta (193-195)) | Trials (interleukin 1beta (193-195)) | Recent Studies (post-2010) (interleukin 1beta (193-195)) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 18 | 0 | 2 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, M; Eberle, A; Gibbons, NC; Kokot, A; Luger, TA; Mastrofrancesco, A; Picardo, M; Schallreuter, KU; Strozyk, E; Zouboulis, CC | 1 |
1 other study(ies) available for interleukin 1beta (193-195) and interleukin-8
| Article | Year |
|---|---|
KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes.
Topics: alpha-MSH; Animals; Cell Line; Cell Line, Transformed; Cytokines; DNA-Binding Proteins; Humans; I-kappa B Kinase; I-kappa B Proteins; Immunosuppressive Agents; Interleukin-1beta; Interleukin-6; Interleukin-8; Melanoma, Experimental; Mice; NF-KappaB Inhibitor alpha; Peptide Fragments; Sebaceous Glands; Signal Transduction | 2010 |